Sildenafil reduces insulin-resistance in human endothelial cells

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Mammi, Caterina ^a   Pastore, Donatella ^b   Lombardo, Marco F ^b   Ferrelli, Francesca ^b   Caprio, Massimiliano ^a   Consoli, Claudia ^c   Tesauro, Manfredi ^b   Gatta, Lucia ^c   Fini, Massimo ^c   Federici, Massimo ^b   Sbraccia, Paolo ^b   Donadel, Giulia ^b   Bellia, Alfonso ^b   Rosano, Giuseppe M ^c   Fabbri, Andrea ^b   Lauro, Davide ^b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c San Raffaele Sulmona ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSAMINE; INSULIN; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE V; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; SERINE; SILDENAFIL; NOS3 PROTEIN, HUMAN; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE; VASODILATOR AGENT;

ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; INSULIN RESISTANCE; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; VASODILATATION; CELL CULTURE; CYTOLOGY; DRUG EFFECT; GENETICS; VASCULAR ENDOTHELIUM;

CELLS, CULTURED; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN; INSULIN RESISTANCE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RNA, MESSENGER; SULFONES; VASODILATOR AGENTS;

EID: 79551522184     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014542     Document Type: Article

References (40)

1. Fleming I, Bauersachs J, Schafer A, Scholz D, Aldershvile J, et al. (1999) Isometric contraction induces the Ca2+-independent activation of the endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 96: 1123-1128.
2. Butt E, Bernhardt M, Smolenski A, Kotsonis P, Frohlich LG, et al. (2000) Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. J Biol Chem 275: 5179-5187.
3. Michel T, Li GK, Busconi L (1993) Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 90: 6252-6256.
4. Fleming I, Bauersachs J, Fisslthaler B, Busse R (1998) Ca2+-independent activation of the endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid shear stress. Circ Res 82: 686-695.
5. Michell BJ, Chen Z, Tiganis T, Stapleton D, Katsis F, et al. (2001) Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 276: 17625-17628.
6. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, et al. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605.
7. Zeng G, Quon MJ (1996) Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 98: 894-898.
8. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, et al. (2000) Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101: 1539-1545.
9. Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, et al. (2002) Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 106: 466-472.
10. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, et al. (2000) Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 36: 845-851.
11. Prasad S, Wilkinson J, Gatzoulis MA (2000) Sildenafil in primary pulmonary hypertension. N Engl J Med 343: 1342.
12. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, et al. (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104: 1218-1222.
13. Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, et al. (2002) Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 33: 2675-2680.
14. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, et al. (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105: 2398-2403.
15. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR (2003) Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107: 3230-3235.
16. Reffelmann T, Kloner RA (2003) Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 108: 239-244.
17. Abrams D, Schulze-Neick I, Magee AG (2000) Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84: E4.
18. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, et al. (1996) Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97: 2601-2610.
19. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA (2002) Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 25: 1336-1339.
20. Park K, Ryu KS, Li WJ, Kim SW, Paick JS (2008) Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction. Eur Urol 53: 1282-1288.
21. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, et al. (2007) Chronic treatment with sildenafil improves energy balance and insulin action in high fatfed conscious mice. Diabetes 56: 1025-1033.
22. Hsueh WA, Lyon CJ, Quinones MJ (2004) Insulin resistance and the endothelium. Am J Med 117: 109-117.
23. Hadi HA, Suwaidi JA (2007) Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 3: 853-876.
24. Deedwania PC (2004) Diabetes is a vascular disease: the role of endothelial dysfunction in pathophysiology of cardiovascular disease in diabetes. Cardiol Clin 22: 505-9, v.
25. Francis SH, Sekhar KR, Rouse AB, Grimes KA, Corbin JD (2003) Single step isolation of sildenafil from commercially available Viagra tablets. Int J Impot Res 15: 369-372.
26. Luedders DW, Muenz BM, Li F, Rueckleben S, Tillmanns H, et al. (2006) Role of cGMP in sildenafil-induced activation of endothelial Ca2+-activated K+ channels. J Cardiovasc Pharmacol 47: 365-370.
27. Chou SH, Chai CY, Wu JR, Tan MS, Chiu CC, et al. (2006) The effects of debanding on the lung expression of ET-1, eNOS, and cGMP in rats with left ventricular pressure overload. Exp Biol Med (Maywood) 231: 954-959.
28. Song P, Wu Y, Xu J, Xie Z, Dong Y, et al. (2007) Reactive nitrogen species induced by hyperglycemia suppresses Akt signaling and triggers apoptosis by upregulating phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10) in an LKB1-dependent manner. Circulation 116: 1585-1595.
29. Nelson BA, Robinson KA, Buse MG (2002) Defective Akt activation is associated with glucose- but not glucosamine-induced insulin resistance. Am J Physiol Endocrinol Metab 282: E497-E506.
30. Montagnani M, Chen H, Barr VA, Quon MJ (2001) Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem 276: 30392-30398.
31. Zeng G, Quon MJ (1996) Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 98: 894-898.
32. Favot L, Keravis T, Holl V, Le Bec A, Lugnier C (2003) VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost 90: 334-343.
33. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, et al. (2000) Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 101: 676-681.
34. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R (2001) Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 88: E68-E75.
35. Puerta E, Hervias I, Goni-Allo B, Lasheras B, Jordan J, et al. (2009) Phosphodiesterase 5 inhibitors prevent 3,4-methylenedioxymethamphetamineinduced 5-HT deficits in the rat. J Neurochem 108: 755-766.
36. Bivalacqua TJ, Sussan TE, Gebska MA, Strong TD, Berkowitz DE, et al. (2009) Sildenafil inhibits superoxide formation and prevents endothelial dysfunction in a mouse model of secondhand smoke induced erectile dysfunction. J Urol 181: 899-906.
37. Milara J, Juan G, Ortiz JL, Guijarro R, Losada M, et al. (2010) Cigarette smokeinduced pulmonary endothelial dysfunction is partially suppressed by sildenafil. Eur J Pharm Sci 39: 363-372.
38. Alvarado-Vasquez N, Zapata E, Alcazar-Leyva S, Masso F, Montano LF (2007) Reduced NO synthesis and eNOS mRNA expression in endothelial cells from newborns with a strong family history of type 2 diabetes. Diabetes Metab Res Rev.
39. Salt IP, Morrow VA, Brandie FM, Connell JM, Petrie JR (2003) High glucose inhibits insulin-stimulated nitric oxide production without reducing endothelial nitric-oxide synthase Ser1177 phosphorylation in human aortic endothelial cells. J Biol Chem 278: 18791-18797.
40. Ball LE, Berkaw MN, Buse MG (2006) Identification of the major site of Olinked beta-N-acetylglucosamine modification in the C terminus of insulin receptor substrate-1. Mol Cell Proteomics 5: 313-323.